These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9095206)

  • 21. Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance.
    Martin DS; Stolfi RL; Sawyer RC; Spiegelman S; Casper ES; Young CW
    Cancer Res; 1983 May; 43(5):2317-21. PubMed ID: 6187448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine.
    Erlichman C; Vidgen D
    Biochem Pharmacol; 1984 Oct; 33(20):3177-81. PubMed ID: 6487365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin.
    Budihardjo II; Walker DL; Svingen PA; Buckwalter CA; Desnoyers S; Eckdahl S; Shah GM; Poirier GG; Reid JM; Ames MM; Kaufmann SH
    Clin Cancer Res; 1998 Jan; 4(1):117-30. PubMed ID: 9516960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I trial of the combination of 6-methylmercaptopurine riboside and 5-fluorouracil.
    Wiemann MC; Crabtree GW; Weitberg AB; Spremulli EN; Cummings FJ; Murray C; Calabresi P
    Med Oncol Tumor Pharmacother; 1988; 5(2):113-6. PubMed ID: 3412035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model.
    Plum SM; Hanson AD; Volker KM; Vu HA; Sim BK; Fogler WE; Fortier AH
    Clin Cancer Res; 2003 Oct; 9(12):4619-26. PubMed ID: 14555538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
    Chan TC; Markman M; Cleary S; Howell SB
    Cancer Res; 1986 Jun; 46(6):3168-72. PubMed ID: 3698032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
    Fleming RA; Capizzi RL; Muss HB; Smith S; Fernandes DJ; Homesley H; Loggie BW; Case L; Morris R; Russell GB; Richards F
    Clin Cancer Res; 1996 Jul; 2(7):1107-14. PubMed ID: 9816275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of human ovarian tumor cell sensitivity to N-(phosphonacetyl)-L-aspartate (PALA) by liposome drug carriers.
    Sharma A; Straubinger NL; Straubinger RM
    Pharm Res; 1993 Oct; 10(10):1434-41. PubMed ID: 8272404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
    Hageboutros A; Rogatko A; Newman EM; McAleer C; Brennan J; LaCreta FP; Hudes GR; Ozols RF; O'Dwyer PJ
    Cancer Chemother Pharmacol; 1995; 35(3):205-12. PubMed ID: 7805178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxicity of aziridinylbenzoquinone for aerobic and hypoxic cells of a transplanted mouse mammary tumor and interaction of the drug with radiation and adriamycin.
    Tannock I
    Cancer Res; 1983 May; 43(5):2059-62. PubMed ID: 6831436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
    Ardalan B; Ucar A; Reddy R; Livingstone AS; Markoe A; Schwade J; Richman SP; Donofrio K
    Cancer; 1994 Oct; 74(7):1869-73. PubMed ID: 8082092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase-I trial of combination therapy with continuous-infusion MMPR and continuous-infusion 5-FU.
    Peters WP; Weiss G; Kufe DW
    Cancer Chemother Pharmacol; 1984; 13(2):136-8. PubMed ID: 6205781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of low-dose PALA in biochemical modulation.
    O'Dwyer PJ
    Pharmacol Ther; 1990; 48(3):371-80. PubMed ID: 2084707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PALA enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells.
    Yang JL; Fernandes DJ; Wheeler KT; Capizzi RL
    Int J Radiat Oncol Biol Phys; 1996 Mar; 34(5):1073-9. PubMed ID: 8600090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl) methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice.
    Peterson CM; Lu JM; Sun Y; Peterson CA; Shiah JG; Straight RC; Kopecek J
    Cancer Res; 1996 Sep; 56(17):3980-5. PubMed ID: 8752167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
    Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG
    Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of the antitumour activity of cisplatin alone and in combination with 5-fluoro-2'-deoxyuridine by N-phosphonacetyl-L-aspartate in murine colon carcinoma no. 26.
    Van Laar JA; Mayhew EG; Cao S; Durrani FA; Peters GJ; Rustum YM
    Eur J Cancer; 1995 Jun; 31A(6):974-6. PubMed ID: 7646931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.
    Chan TC; Howell SB
    Cancer Res; 1985 Aug; 45(8):3598-604. PubMed ID: 4016741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytological effects of sulfur and selenium purine analogues on two transplantable hepatomas and on normal renewing cells in mice.
    Melvin JB; Haight TH; Leduc EH
    Cancer Res; 1984 Jul; 44(7):2794-8. PubMed ID: 6722809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of 6-aminonicotinamide and other protein synthesis inhibitors on formation of platinum-DNA adducts and cisplatin sensitivity.
    Budihardjo II; Boerner SA; Eckdahl S; Svingen PA; Rios R; Ames MM; Kaufmann SH
    Mol Pharmacol; 2000 Mar; 57(3):529-38. PubMed ID: 10692493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.